Aligos Therapeutics (ALGS) Cash from Financing Activities (2019 - 2026)
Aligos Therapeutics (ALGS) reported Cash from Financing Activities of -$62000.0 for Q1 2026, down 100.06% on a YoY basis from $101.7 million in Q1 2025, and down 150.41% quarter-over-quarter from $123000.0 in Q4 2025.
Aligos Therapeutics (ALGS) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Aligos Therapeutics has reported Cash from Financing Activities for 8 years, with the latest figure at -$62000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 100.06% year-over-year to -$62000.0; the trailing twelve-month figure through Mar 2026 stood at -$169000.0 (down 100.17% YoY), and the FY2025 full-year result was $101.6 million, up 28529.58% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$62000.0, down from $123000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $101.7 million in Q1 2025, with the low at -$177000.0 in Q2 2025.
- Historically, Cash from Financing Activities has averaged $11.2 million across 5 years, with a median of -$1000.0 in 2023.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities slumped 1800.0% — and 2025, when it soared 535584.21%.
- Aligos Therapeutics' Cash from Financing Activities stood at $121000.0 in 2022, then soared by 72574.38% to $87.9 million in 2023, then plunged by 99.89% to $97000.0 in 2024, then climbed by 26.8% to $123000.0 in 2025, then tumbled by 150.41% to -$62000.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$62000.0 (Q1 2026), $123000.0 (Q4 2025), and -$53000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 85,464.43 |
| 10 | Aligos Therapeutics | 51.70 Mn | -28.13 Mn | - | -62,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -62,000.00 |
| Mar 31, 2026 | -62,000.00 |
| Dec 31, 2025 | 123,000.00 |
| Dec 31, 2025 | 123,000.00 |
| Sep 30, 2025 | -53,000.00 |
| Sep 30, 2025 | -53,000.00 |
| Jun 30, 2025 | -177,000.00 |
| Jun 30, 2025 | -177,000.00 |
| Mar 31, 2025 | 101.74 Mn |
| Mar 31, 2025 | 101.74 Mn |
| Dec 31, 2024 | 97,000.00 |
| Dec 31, 2024 | 97,000.00 |
| Sep 30, 2024 | -4,000.00 |
| Sep 30, 2024 | -4,000.00 |
| Jun 30, 2024 | 281,000.00 |
| Jun 30, 2024 | 281,000.00 |
| Mar 31, 2024 | -19,000.00 |
| Mar 31, 2024 | -19,000.00 |
| Dec 31, 2023 | 87.94 Mn |
| Dec 31, 2023 | 87.94 Mn |